Dual-Inhibition of mTOR and Bcl-2 Enhances the Anti-tumor Effect of Everolimus against Renal Cell Carcinoma In Vitro and In Vivo

Renal cell carcinoma (RCC) is the predominant type of kidney cancer. Mammalian target of rapamycin (mTOR) inhibitor everolimus is currently used as a second-line therapy for sorafenib or sunitinib-refractory metastatic RCC patients. The clinical limitation confronted during everolimus therapy is the...

Descripción completa

Detalles Bibliográficos
Autores principales: Nayman, Ayse Hande, Siginc, Halime, Zemheri, Ebru, Yencilek, Faruk, Yildirim, Asif, Telci, Dilek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485234/
https://www.ncbi.nlm.nih.gov/pubmed/31031856
http://dx.doi.org/10.7150/jca.29192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485234/
https://www.ncbi.nlm.nih.gov/pubmed/31031856
http://dx.doi.org/10.7150/jca.29192

Ejemplares similares